T0	Participants 54 95	patients with tuberous sclerosis complex:
T1	Participants 235 334	patients with subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex
T2	Participants 459 484	data (up to Jan 11, 2013)
T3	Participants 747 841	in patients with tuberous sclerosis complex who had SEGA that was growing and needed treatment
T4	Participants 871 1128	included all patients who had been assigned everolimus during the double-blind, randomised phase of the trial and those patients who crossed over from the placebo group to receive everolimus during the randomised phase or at the start of the extension phase
T5	Participants 1701 1810	the original 117 randomly assigned patients, 111 were given everolimus between Aug 20, 2009, and Jan 11, 2013
T6	Participants 2961 3070	everolimus in patients who have few treatment options and who need continued treatment for tuberous sclerosis